Your browser doesn't support javascript.
loading
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis.
Magro, Fernando; Moreira, Paula Leão; Catalano, Gaia; Alves, Catarina; Roseira, Joana; Estevinho, Maria Manuela; Silva, Isabel; Dignass, Axel; Peyrin-Biroulet, Laurent; Danese, Silvio; Jairath, Vipul; Dias, Claudia Camila; Santiago, Mafalda.
Afiliação
  • Magro F; Department of Gastroenterology, São João University Hospital Center, Porto, Portugal.
  • Moreira PL; Clinical Pharmacology Unit, São João University Hospital Center, Porto, Portugal.
  • Catalano G; Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Alves C; CINTESIS-Center for Health Technology and Services Research, Porto, Portugal.
  • Roseira J; RISE-Health Research Network, Porto, Portugal.
  • Estevinho MM; GEDII-Portuguese Inflammatory Bowel Disease Study Group, Porto, Portugal.
  • Silva I; Clinical Pharmacology Unit, São João University Hospital Center, Porto, Portugal.
  • Dignass A; Università Vita-Salute San Raffaele, Milan, Italy.
  • Peyrin-Biroulet L; Faculty of Medicine, University of Porto, Porto, Portugal.
  • Danese S; Gastroenterology Department, Algarve University Hospital Center, Faro, Portugal.
  • Jairath V; ABC-Algarve Biomedical Center, Loulé, Portugal.
  • Dias CC; Department of Gastroenterology, Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Vila Nova de Gaia, Portugal.
  • Santiago M; Clinical Pharmacology Unit, São João University Hospital Center, Porto, Portugal.
United European Gastroenterol J ; 11(2): 202-217, 2023 03.
Article em En | MEDLINE | ID: mdl-36876515
ABSTRACT
BACKGROUND AND

AIMS:

The availability of biological agents for inflammatory bowel disease has increased over the past years. In this systematic review and meta-analysis, we aimed to explore time trends in clinical response and clinical remission rates in Crohn's disease (CD) patients treated with biologics while discussing the need for new strategies.

METHODS:

MEDLINE, Cochrane, and ISI Web of Science databases were searched for randomized placebo-controlled trials with biological agents in moderate-to-severe CD patients. Sub-group and meta-regression analyses compared treatment and placebo by calculating the pooled odds ratios of clinical remission and clinical response, across time categories and publication year. We also estimated the proportion of patients achieving clinical remission and clinical response by comparing both groups according to the publication year.

RESULTS:

Twenty-five trials were included in the systematic review, which enrolled 8879 patients between 1997 and 2022. The clinical remission and clinical response odds, in induction and maintenance, have been constant over time, as no statistically significant differences were found between time categories (interaction p-values clinical remission [induction, p = 0.19; maintenance, p = 0.24]; clinical response [induction, p = 0.43; maintenance, p = 0.59]). In meta-regression analyses, publication year did not influence these outcomes (clinical remission [induction, OR 1.01{95% CI 0.97-1.05}, p = 0.72; clinical response [induction, OR 1.01{95% CI 0.97-1.04]; p = 0.63; maintenance, OR 1.03{95% CI 0.98-1.07}; p = 0.21]), with the exception of clinical remission in maintenance studies, which presented a decreased effect (odds ratio 0.97{95% CI 0.94-1.00}, p = 0.03]).

CONCLUSIONS:

Our review highlights that the odds of clinical outcomes in CD patients receiving biological treatment relative to placebo have been stable in the last decades.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn Idioma: En Ano de publicação: 2023 Tipo de documento: Article